INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company’s possible violations of federal securities laws.

On April 29, 2024, Annovis announced that its Alzheimer’s drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the total planned patients, indicating that the drug failed to show statistical significance in meeting its endpoints.

On this news, Annovis’s stock price fell $10.37, or 59.6%, to close at $7.28 per share on April 29, 2024, thereby injuring investors.

If you purchased Annovis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.